Svas Biosana S p A : Successful debut on EURONEXT GROWTH MILAN market for SVAS Biosana

COMUNICATO STAMPA

• SUCCESSFUL DEBUT ON EURONEXT GROWTH MILAN MARKET FOR SVAS BIOSANA
• SUSPENDED TO THE UPSIDE IN THE FIRST DAY OF TRADING
• CLOSING PRICE AT € 14.49 PER SHARE (+ 15,92% OF OFFER PRICE)
• ANDREA EFFICACE APPOINTED INVESTOR RELATIONS MANAGER OF SVAS BIOSANA

Somma Vesuviana (NA) 9th December 2021 - Svas Biosana S.p.A., ("the Company" or "SVAS"), a leading operator in the healthcare sector, active in the production and distribution of medical devices for public and private healthcare facilities, announces that trading of its ordinary shares and "Warrants Svas Biosana 2021- 2024" commenced today on the Euronext Growth Milan market, a multilateral trading system organised and managed by Borsa Italiana S.p.A. dedicated to small and medium-sized companies with high growth potential.

The company's stock at the opening rose 12.82% to €14.102, after hitting a high of €15. The shares closed the trading session with a price of € 14.49, up 16% from the offer price of € 12.50, with strong demand from investors who showed great interest and appreciation in the Company. At the end of the first day of trading, the capitalisation of Svas reached € 81,1 million.

"The first day of trading in SVAS shares has been very exciting" says Umberto Perillo, CEO of SVAS Biosana S.p.A., "and we thank the market and investors for their interest and trust. During a complex morning that saw a high volatility of many stocks with strong peaks and troughs, our stock has maintained a linear trend starting from the delayed opening due to overbought, then closing positively and reaching almost € 15. We are therefore very satisfied with the performance of today's trading on our debut".

"We are delighted to have accompanied Svas Biosana on its way to the stock exchange" - comments Alessio Muretti, Deputy Head of Investment Banking at Banca Profilo - "with a placement that attracted a great deal of interest from Italian investors and a significant number of high standing international investors. We received more than three times as much demand as supply, confirming the attention given to Svas by the capital market. Banca Profilo's objective is to select excellent Italian companies and support them in their IPO and M&A processes, helping them to achieve the best possible valuation with investors with the right mix of Italian and international institutions contributing to broaden the companies' shareholder base. We believed in SVAS and its top management and the market has confirmed our vision".

SVAS also announces that - in accordance with the provisions of the Euronext Growth Milan Issuers' Regulation which contemplates the appointment and disclosure of the Investor Relator Manager - Mr. Andrea Efficace, formerly CFO of the Group, was appointed Investor Relator Manager at the meeting of the Board of Directors on the 22nd November 2021. Andrea Efficace guided Svas Biosana in its listing process on the Euronext Growth Milan market with the start of trading today.

In the listing process, Svas Biosana S.p.A. is assisted by Banca Profilo (Euronext Growth Advisor and Joint- Global Coordinator of the transaction), illimity Bank (Joint Global Coordinator of the transaction), Banca Finint (Financial Advisor of the Issuer), Grimaldi Studio Legale (Legal Advisor of the Issuer and of the Joint Global Coordinators), PwC Italia (Auditing Company), A2B Group (Advisor for non-accounting data) and Polytems HIR (Communication Advisor).

This press release is available at Borsa Italiana, at the Company's registered office, and in the Investor Relations/Financial Communications section of the website www.svas.it. For the dissemination of regulated information, Svas Biosana uses the eMarket SDIR circuit, managed by Spafid Connect S.p.A., with registered office at Foro Buonaparte 10, Milan (www.emarketstorage.com).

Contacts:

Svas Biosana manufactures and distributes medical devices in Italy and abroad. Founded in 1972 in Somma Vesuviana (NA) by the Perillo family, today SVAS is an international company with a list of about 16,000 products under its own and third party brands, 367 employees, a department dedicated to Research and Development, 3 production plants in Italy and subsidiary companies in Slovenia, Croatia, Serbia and Bosnia Herzegovina.

Tickers: ISIN Ordinary shares: IT0005469264 - ISIN Warrant SVAS BIOSANA 2021-2024: IT0005469157